School of Science Division of Life Science 25 Human Complex Disease Genomics and Bioinformatics Supervisor: LIANG Chun / LIFS Co-supervisor: XUE Hong / LIFS Student: WING Yui Yan / DASC Course: UROP 1000, Summer This study compares feature enrichment patterns in high-frequency copy number variations (CNVs) using fixed window sizes ranging from 50 to 500 kb between schizophrenia with 26 sample sets and lung cancer with 38 sample sets. Analyzing genomic features across genic, proximal, and distal zones revealed shared patterns within including enrichment of histone modifications and CpG features in CNV loss regions, alongside consistent depletion of Alu family elements. Both CNVG and CNVL region showed enrichment of various size-class CNVs in marker features, while only SNPs mapped to multiple locations demonstrated consistent enrichment. Apart from similarity, SNPM is enriched exclusively in schizophrenia while RecD specifically enriched in lung cancer CNV loss regions. These findings suggest common mechanisms of genomic instability underlie these distinct conditions, providing potential targets for biomarker development and therapeutic intervention. Potential Cancer Drug Identification and Characterization Supervisor: LIANG Chun / LIFS Student: GANGULI Srishti / BIOT-AB Course: UROP 1100, Spring Cervical cancer, driven by persistent HPV infection, remains a leading cause of cancer mortality in women worldwide. While platinum-based therapies are first-line treatments, their systemic toxicity and acquired resistance underscore the need for novel chemotherapeutic agents. This study investigates the cytotoxic potential of two synthetic compounds, AA438 and AA420, in HeLa cells, a well-established model for HPVrelated oncogenesis. HeLa cells were treated with AA438 or AA420 (0.78125–100 mM) for 72 hours, and viability was assessed using a CCK-8 assay. Dose-response curves were generated via four-parameter logistic (4PL) modeling to determine half-maximal inhibitory concentrations (IC50). AA438 exhibited superior potency with an IC50 of 4.784 mM, reducing viability to 3.44% at 100 mM. AA420 showed moderate activity (IC50 = 6.866 mM), consistent with structural predictions. Both compounds demonstrated steep Hill slopes (>1.5), suggesting cooperative target engagement. AA438’s 2.3-fold greater potency than AA420 positions it as a promising lead compound for cervical cancer therapy. Further studies are warranted to elucidate its mechanism of action and in vivo efficacy.
RkJQdWJsaXNoZXIy NDk5Njg=